ShiraTronics

Executive Summary

ShiraTronics is a private medical device company headquartered in Minneapolis, MN, focused on developing a novel fully implantable neuromodulation system for the treatment of chronic migraine. Founded in 2018, the company targets a large unmet need: the over 1 billion people worldwide affected by migraine, with approximately 10% suffering from chronic migraine. Current pharmacological treatments often have limited efficacy and significant side effects, while non-invasive neuromodulation devices offer limited duration of relief. ShiraTronics' approach involves continuous targeted electrical stimulation to peripheral nerves in the head, aiming to interrupt and prevent migraine symptoms. The device is designed for long-term implantation, offering a chronic therapy option. The company is still in the clinical stage, with no publicly disclosed funding rounds or revenue, indicating an early development phase. However, the potential for a differentiated, durable therapy positions ShiraTronics favorably in the neuromodulation space, which has seen increasing investor interest.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Pivotal Clinical Trial75% success
• Q2 2026FDA Breakthrough Device Designation65% success
• H1 2026Series A or B Financing Round80% success